Article Details
Retrieved on: 2021-05-14 15:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... combining melphalan flufenamide (Melflufen) with proteasome inhibitors (PIs) and anti-CD38 monoclonal antibodies is an active area of interest.
Article found on: www.onclive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here